Y320 - CAS 288250-47-5
Catalog number: 288250-47-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Interleukin Related
Y-320 is a new phenylpyrazoleanilide immunomodulator that inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.
Y-320; Y320; Y 320
Canonical SMILES:
1.Allosteric coupling in pyruvate dehydrogenase kinase 2.
Klyuyeva A;Tuganova A;Popov KM Biochemistry. 2008 Aug 12;47(32):8358-66. doi: 10.1021/bi800631h. Epub 2008 Jul 16.
Mitochondrial pyruvate dehydrogenase kinase 2 (PDHK2) phosphorylates the pyruvate dehydrogenase multienzyme complex (PDC) and thereby controls the rate of oxidative decarboxylation of pyruvate. The activity of PDHK2 is regulated by a variety of metabolites such as pyruvate, NAD (+), NADH, CoA, and acetyl-CoA. The inhibitory effect of pyruvate occurs through the unique binding site, which is specific for pyruvate and its synthetic analogue dichloroacetate (DCA). The effects of NAD (+), NADH, CoA, and acetyl-CoA are mediated by the binding site that recognizes the inner lipoyl-bearing domain (L2) of the dihydrolipoyl transacetylase (E2). Both allosteric sites are separated from the active site of PDHK2 by more than 20 A. Here we show that mutations of three amino acid residues located in the vicinity of the active site of PDHK2 (R250, T302, and Y320) make the kinase resistant to the inhibitory effect of DCA, thereby uncoupling the active site from the allosteric site. In addition, we provide evidence that substitutions of R250 and T302 can partially or completely uncouple the L2-binding site. Based on the available structural data, R250, T302, and Y320 stabilize the "open" and "closed" conformations of the built-in lid that controls the access of a nucleotide into the nucleotide-binding cavity.
2.Cooperative binding of the class I major histocompatibility complex cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu subunit.
Noviello CM;Benichou S;Guatelli JC J Virol. 2008 Feb;82(3):1249-58. Epub 2007 Dec 5.
Human immunodeficiency virus type 1 Nef provides immune evasion by decreasing the expression of major histocompatibility complex class I (MHC-I) at the surfaces of infected cells. The endosomal clathrin adaptor protein complex AP-1 is a key cellular cofactor for this activity, and it is recruited to the MHC-I cytoplasmic domain (CD) in the presence of Nef by an uncharacterized mechanism. To determine the molecular basis of this recruitment, we used an MHC-I CD-Nef fusion protein to represent the MHC-I CD/Nef complex during protein interaction assays. The MHC-I CD had no intrinsic ability to bind AP-1, but it conferred binding activity when fused to Nef. This activity was independent of the canonical leucine-based AP-binding motif in Nef; it required residue Y320 in the MHC-I CD and residues E62-65 and P78 in Nef, and it involved the mu but not the gamma/sigma subunits of AP-1. The impaired binding of mutants encoding substitutions of E62-65 or P78 in Nef was rescued by replacing the Y320SQA sequence in the MHC-I CD with YSQL, suggesting that Nef allows the YSQA sequence to act as if it were a canonical mu-binding motif. These data identify the mu subunit of AP-1 (mu1) as the key target of the MHC-I CD/Nef complex, and they indicate that both Y320 in the MHC-I CD and E62-65 in Nef interact directly with mu1.
3.A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist.
Kane BE;Nieto MJ;McCurdy CR;Ferguson DM FEBS J. 2006 May;273(9):1966-74.
Salvinorin A is a potent kappa opioid receptor (KOP) agonist with unique structural and pharmacological properties. This non-nitrogenous ligand lacks nearly all the structural features commonly associated with opioid ligand binding and selectivity. This study explores the structural basis to salvinorin A binding and selectivity using a combination of chimeric and single-point mutant opioid receptors. The experiments were designed based on previous models of salvinorin A that locate the ligand within a pocket formed by transmembrane (TM) II, VI, and VII. More traditional sites of opioid recognition were also explored, including the highly conserved aspartate in TM III (D138) and the KOP selectivity site E297, to determine the role, if any, that these residues play in binding and selectivity. The results indicate that salvinorin A recognizes a cluster of residues in TM II and VII, including Q115, Y119, Y312, Y313, and Y320. Based on the position of these residues within the receptor, and prior study on salvinorin A, a model is proposed that aligns the ligand vertically, between TM II and VII. In this orientation, the ligand spans residues that are spaced one to two turns down the face of the helices within the receptor cavity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Interleukin Related Products

CAS 541550-19-0 Apilimod

(CAS: 541550-19-0)

Apilimod is a potent and orally bioavailable inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain au...

CAS 2826-26-8 Tyrphostin A1

Tyrphostin A1
(CAS: 2826-26-8)

Tyrphostin A1, can be as a negative control for inhibition of EGFR (IC50 >1250 µM) and was shown to inhibit the tyrosine phosphorylation of IL-2 stimulated Tyk-...

CAS 1232221-74-7 APY0201

(CAS: 1232221-74-7)

APY0201, an effective IL-12/23 inhibitor, has been found to have potential useful in treatment of inflammation. IC50: 5.2 nM .

CAS 755013-59-3 Veledimex racemate

Veledimex racemate
(CAS: 755013-59-3)

Veledimex racemate is the racemate of veledimex. Veledimex is an orally active small molecule diacylhydrazine and controls the expression of the target gene.

CAS 86727-00-6 CK 17

CK 17
(CAS: 86727-00-6)

CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation.

CAS 14937-32-7 Pentagalloylglucose

(CAS: 14937-32-7)

Pentagalloylglucose, a polyphenol isolated from the fruits of Pistacia lentiscus, increases a population of Treg cells in conjunction with Treg-inducing factors...

CAS 849776-05-2 Ladarixin

(CAS: 849776-05-2)

Ladarixin is Interleukin 8A and Interleukin 8B receptor antagonist. IL-8A and IL-8B inhibition blocks and reverses type 1 diabetes in mice. In Dec 2015, Phase-I...

CAS 640736-79-4 PD 0220245

PD 0220245
(CAS: 640736-79-4)

PD 0220245 is a non-peptide interleukine 8 (IL-8) receptor antagonist.

Chemical Structure

CAS 288250-47-5 Y320

Quick Inquiry

Verification code

Featured Items